(Q43882700)

English

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

scientific article published in January 2002

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

0 references

(RS)-sibutramine

1 reference

based on heuristic

inferred from title

author name string

F G McMahon

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

S P Weinstein

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

E Rowe

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

K R Ernst

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

F Johnson

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

K Fujioka

6

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sibutramine in Hypertensives Clinical Study Group

7

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Journal of Human Hypertension

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

5-11

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

21 January 2018

Health implications of overweight and obesity in the United States

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

21 January 2018

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

21 January 2018

Sibutramine produces dose-related weight loss

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

21 January 2018

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

21 January 2018

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

21 January 2018

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

21 January 2018

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

21 January 2018

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

21 January 2018

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

21 January 2018

Obesity and Heart Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

7 January 2021

based on heuristic

inferred from DOI database lookup

Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

7 January 2021

based on heuristic

inferred from DOI database lookup

Thermogenic effects of sibutramine in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

7 January 2021

based on heuristic

inferred from DOI database lookup

American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

7 January 2021

based on heuristic

inferred from DOI database lookup

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

7 January 2021

based on heuristic

inferred from DOI database lookup

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001298

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.JHH.1001298

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43882700&oldid=2206313030"